Thank you for downloading!
Check out more content that may interest you and follow us on social media
The latest from Median
eyonis® LCS has obtained CE marking as a Class IIb medical device, under the new European Medical Device Regulation (MDR 2017/745), enabling commercialization across the European Economic Area.
Median Technologies today reported its 2025 consolidated annual financial results, and provided key business highlights for the first quarter of 2026.
Median Technologies announces collaboration with Tempus to expand access to eyonis® LCS Software as a Medical Device in the United States
Median Technologies receives FDA 510(k) clearance for eyonis® LCS, the first AI tech-based detection and diagnosis device for lung cancer screening
Conferences
October 23 – 27, 2026ESMO 2026
Median will be exhibiting at the ESMO Congress on October 23 – 27 in Madri. Happy to see you there at IFEMA Madrid!
Webinars
Using Imaging in Clinical Trials to Improve Data and Decisions
Watch the recording of this webinar to gain actionable insights into building and strategizing imaging in clinical trials to minimize risk, reduce delays and set the stage for smarter trials.